“Global Metabolic Disorder Therapeutics market is anticipated to surpass USD 100 Billion by 2030”,says Visiongain

16 October 2019
Pharma

Visiongain has launched a new pharma report of ‘’Metabolic Disorder Therapeutics Market Report’’ by Route of Administration (Oral Administration, Parenteral Administration, Other Route of Administration), Therapy Type (Cellular Transplantation, Enzyme Replacement Therapy, Small Molecule-Based Therapy, Gene Therapy, Substrate Reduction Therapy, Drug Therapy), Disease (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia), and Geography.

The global Metabolic Disorder Therapeutics market is anticipated to grow at a lucrative CAGR of 6.7% and anticipated to surpass USD 100 Billion by 2030.

Metabolic disorders interfere with the ordinary function of metabolic processes, resulting in excess or absence of vital parts required to remain healthy. During an individual's lifetime, these diseases are either inherited or obtained. Increasing demand for one-time therapies for metabolic disorders and increasing lifestyle disorder incidences are the major factors anticipated to increase this market's development. Several governments and healthcare organizations around the globe have estimated that by 2040, over half a billion people will be impacted by obesity and diabetes. Furthermore, increasing incidences of hereditary metabolic diseases due to evolving lifestyles are likely to drive market growth.

The market for metabolic disorder therapeutics is segmented based on disease, route of administration, therapy type, and region. Based on disease, the global market is further sub-segmented into diabetes, lysosomal storage diseases, inherited metabolic disorders, obesity, hypercholesterolemia. Diabetes is anticipated to dominate the global metabolic disorder therapeutics market owing to the comprehensive use of metabolic disease therapies in anti-diabetic injections, drugs, and injections to control bloodsugar levels.

North America holds the majority of market share followed by Europe and will continue to dominate in the first half of the forecast period owing to the presence of major companies, increasing prevalence/incidence cases of obesity and diabetes, rising healthcare expenditure, and growing awareness for metabolic disorders among other contributing growth factors. However, the Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the economic growth in this region, changing lifestyles leading to a rise in obesity, hypercholesterolemia diseases, and diabetes, along with increased disposable income levels.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global metabolic disorder therapeutics market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Abbvie, Actelion Pharmaceuticals Ltd, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, BioMarin, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., CymaBay Therapeutics, Eli Lily and Company, Merck KgaA, Novo Nordisk, Sanofi, and Shire Plc among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever